Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.46 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 13/20 | 0.43 |
| ▸ | JAK3 | P52333 | 12/20 | 0.43 |
| ▸ | JAK2 | O60674 | 10/20 | 0.42 |
| ▸ | TYK2 | P29597 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534021 | 0.79 | CSF1R (0.53) | CSF1RJAK1JAK3JAK2TYK2 | |
| SCHEMBL7589837 | 0.77 | TTBK1 (0.48) | TTBK1TTBK2CSF1RJAK1JAK3 | |
| SCHEMBL7087720 | 0.74 | TTBK1 (0.55) | TTBK1TTBK2 | |
| SCHEMBL7090338 | 0.72 | CSF1R (0.47) | CSF1RJAK1JAK3JAK2TYK2 | |
| SCHEMBL20792859 | 0.71 | CSF1R (0.51) | CSF1RJAK1JAK3JAK2TYK2 | |
| SCHEMBL22877394 | 0.71 | CSF1R (0.51) | CSF1RJAK1JAK3JAK2TYK2 | |
| SCHEMBL7084416 | 0.70 | CSF1R (0.48) | TTBK1TTBK2CSF1RJAK1JAK3 | |
| SCHEMBL7855768 | 0.70 | TTBK1 (0.43) | TTBK1TTBK2CSF1RJAK1JAK3 | |
| SCHEMBL15086982 | 0.69 | JAK3 (0.62) | CSF1RJAK1JAK3JAK2TYK2 | |
| SCHEMBL3578042 | 0.69 | CSF1R (0.58) | TTBK1TTBK2CSF1RJAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | TTBK1 126/4885TTBK2 242/4885CSF1R 334/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | TTBK1 126/4885TTBK2 242/4885CSF1R 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.